A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy

Auteur(s): Annenberg Center for Health Sciences
  • Résumé

  • In this activity, Jeremy Abramson, MD, highlights the significant disease burden of B-cell lymphomas, as well as the latest advances in therapeutics, and practical strategies for integrating novel therapies into practice through patient selection and supportive care management.
    Annenberg Center for Health Sciences
    Voir plus Voir moins
Épisodes
  • Principles of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma: Patient Selection Strategies
    Jun 9 2022

    Large B-cell lymphomas (LBCLs) are one of the most common subtypes of non-Hodgkin lymphomas and while 1st-line standard of care has remained unchanged, the treatment paradigm has undergone a shift in recent years due to the development of novel therapeutic agents. These novel therapies include monoclonal antibody (mAb) therapies, mAb-conjugates, and chimeric antigen receptor (CAR)-T cell therapies.

    Voir plus Voir moins
    8 min
  • Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies
    Jun 9 2022

    Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies

    Voir plus Voir moins
    37 min
  • Disease Burden and Overview of Large B-Cell Lymphomas
    Jun 9 2022

    B-cell lymphomas consist of a heterogenous group of lymphoproliferative neoplasms originating from B-lymphocytes.  

    Voir plus Voir moins
    4 min

Ce que les auditeurs disent de A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.